Skip to main content
Premium Trial:

Request an Annual Quote

GSK to Evaluate Aclara eTag Assays for Cancer Drug Development

NEW YORK, Oct. 5 (GenomeWeb News) - Aclara Biosciences said today that GlaxoSmithKline will evaluate Aclara's eTag assays for their potential use in patient selection for certain GSK targeted cancer therapies.

 

Under the terms of the agreement, GSK will provide Aclara with drug-treated biological samples, and Aclara will test the samples with eTag assays, Aclara said. The companies will then correlate biomarkers with response to the drug.

 

GlaxoSmithKline will provide funding to Aclara for the study, Aclara said, although it did not disclose specific financial details of the agreement.

The Scan

Genetic Risk Factors for Hypertension Can Help Identify Those at Risk for Cardiovascular Disease

Genetically predicted high blood pressure risk is also associated with increased cardiovascular disease risk, a new JAMA Cardiology study says.

Circulating Tumor DNA Linked to Post-Treatment Relapse in Breast Cancer

Post-treatment detection of circulating tumor DNA may identify breast cancer patients who are more likely to relapse, a new JCO Precision Oncology study finds.

Genetics Influence Level of Depression Tied to Trauma Exposure, Study Finds

Researchers examine the interplay of trauma, genetics, and major depressive disorder in JAMA Psychiatry.

UCLA Team Reports Cost-Effective Liquid Biopsy Approach for Cancer Detection

The researchers report in Nature Communications that their liquid biopsy approach has high specificity in detecting all- and early-stage cancers.